Everest Medicines (SEHK:1952) Signs China Cooperation Deal, Is The Stock Cheap?
Everest Medicines stock reacts to new cooperation framework
Everest Medicines (SEHK:1952) drew fresh attention after its China subsidiary signed a multi year Strategic Cooperation Framework Agreement with Hasten Biopharmaceutical to coordinate supply, distribution, manufacturing and commercialization of selected products across the PRC.
The new agreement comes after a choppy run for Everest Medicines, with the share price up 4.71% over the last day and 2.83% over the past week, yet still down 18.06% across 30 days and 27.23% year to date. The 1 year total shareholder return has fallen 52.28%, while the 3 year total shareholder return has risen 31.02%. As a result, recent momentum is building from a low base as investors reassess both growth prospects and execution risk in China.
Scan beyond Everest Medicines and see how other Hong Kong healthcare names are positioned with our curated list of list of solid balance sheet and fundamentals (198 results)
The share price rebound, the heavy one year decline and a near 47% gap to the average analyst target leave Everest Medicines in an awkward middle ground. Does fair value sit closer to recent trading or to those estimates?
Most Popular Narrative: 35% Undervalued
The most followed narrative pegs Everest Medicines at a fair value of HK$42.18, compared with a last close of HK$27.58. This puts the recent rebound in a different light for anyone weighing whether the gap is justified by its pipeline and China exposure.
The company's robust and diversified pipeline spanning mRNA vaccines, in vivo CAR-T, and novel autoimmune therapies with multiple assets moving toward late-stage trials positions Everest to benefit from global moves toward precision and targeted medicines, driving long-term revenue streams and earnings growth from innovative products.
See why 0 investors see Everest Medicines as 35% undervalued.
Result: Fair Value of HK$42.18 (UNDERVALUED)
Still, Everest Medicines faces real pressure if reliance on Nefecon persists and late stage assets stumble in trials or encounter tougher pricing and reimbursement decisions.
Find out about the key risks to this Everest Medicines narrative.
Next Steps
Mixed signals around Everest Medicines often create more questions than answers. Move quickly and stress test the story against the data that matters to you by reviewing the 4 key rewards and 1 important warning sign
Looking for more Everest Medicines investment ideas?
Do not stop with Everest Medicines. Broaden your watchlist with other focused ideas on Simply Wall Street's screener and give yourself more options before the next move.
- Target steady compounders by scanning a 226 resilient stocks with low risk scores that aim to keep downside in check while you hunt for upside elsewhere.
- Hunt for mispriced opportunities using the 180 high quality undervalued stocks that surfaces companies with solid fundamentals trading below their estimated worth.
- Spot future market favorites early through the 613 high quality undiscovered gems filtered for quality businesses that fewer investors are watching.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com